Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAXHER2: T-DM1 + Capecitabine in HER2+ Breast and Gastric Cancer
NCT01702558Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2012
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of trastuzumab emtansine in HER2-positive breast cancer, Gastric cancer (HER2-positive), sponsored by Roche. Started Dec 2012; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
HER2-positive breast cancerGastric cancer (HER2-positive)
Beyond the preview
Go deeper on NCT01702558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01702558.